10 results about "HYPERTENSIVE DISEASES" patented technology

The invention discloses an application of a small molecular compound SR9009 in preparation of antihypertensive drugs. The SR9009 is used for treating three common hypertension rodent animal models, a better antihypertensive effect is shown, the antihypertensive effect is possibly related to increase of urine sodium excretion and reduction of kidney epithelium sodium channel protein expression, possibility is provided for application of the SR9009 in prevention and treatment of hypertension diseases, and the SR9009 has a wide application prospect.

The invention provides a traditional Chinese medicine composition and a preparation method thereof, and belongs to the technical field of traditional Chinese veterinary medicines, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: spring eyes, cynanchum otophyllum, moonwort, gordon euryale seed and the like. The traditional Chinese medicine composition belongs to a pure traditional Chinese medicine preparation, has the effects of calming liver and reducing blood pressure, clearing heat and eliminating phlegm, and tonifying kidney and spleen, and has the advantages of remarkable treatment effect, high blood pressure reducing speed, no toxic or side effect and the like on dog hypertension diseases. The traditional Chinese medicine composition provides a new theoretical data basis and thought for treating the dog hypertension, and has wide market potential in treating the pet dog hypertension diseases.

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 antibody and an anti-sEng antibody bound to a solid support in order to reduce blood levels of sFlt-1 and sEng. The present disclosure relates to methods, systems, devices, and apparatuses for treating pregnancy-related hypertensive disorders such as pre-eclampsia and eclampsia.

The invention provides a construction method and application of an intractable hypertension animal model, and particularly belongs to the technical field of disease animal model construction. The invention provides a construction method of an intractable hypertension animal model, which comprises the following steps: giving high-salt diet to spontaneously hypertensive rats every day, combining with intraperitoneal injection of N '-nitro-L-arginine and subcutaneous injection of testosterone propionate, and continuously administration for 2 weeks to complete modeling. The animal model with the blood pressure difficult to control is constructed, and an experimental tool is provided for scientific research requirements of deep fundamental research, treatment target screening, drug research and development, clinical transformation and the like of refractory hypertension diseases.

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sEng antibody bound to a solid support in order to reduce blood levels of sEng. The present invention provides a method of treating or preventing a disorder associated with soluble Endoglin (sEng), such as a pregnancy-related hypertensive disorder, in a subject in need thereof comprising providing ex vivo to the subject anti-sEng antibodies or sEng-binding fragments thereof in an amount sufficient and for a time sufficient to decrease the subject's blood levels of sEng to treat or prevent the disorder associated with sEng in the subject.

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

The present invention relates to novel sublingual compositions comprising an anti-fibrotic agent, as well as methods for their preparation. Wherein the composition comprising an anti- fibrotic agent such as pirfenidone or nintedanib and its analogs or pharmaceutically acceptable salts thereof. These novel sublingual compositions are intended for use in the treatment of fibrotic diseases, disorders, or conditions, such as idiopathic pulmonary fibrosis (IPF), and hypertensive diseases, disorders, or conditions such as pulmonary hypertension.

The intrauterine hemostasis balloon comprises a guiding assembly and a liquid injection assembly, the guiding assembly comprises a guiding head, a bulb and a flexible catheter, the guiding assembly is used for guiding the intrauterine hemostasis balloon, the guiding head is fixedly connected to the top end of the flexible catheter, and the bulb is fixedly connected to the liquid injection assembly. The guide head penetrates through the bulb and is fixedly connected with the outer surface of the bulb, the interior of the bulb is hollow, the flexible guide pipe penetrates through the bulb and is fixedly connected with the bulb, the liquid injection assembly is jointly composed of a first one-way valve, a sleeve, a piston rod, a liquid injection bag and a connecting pipe, and the liquid injection assembly is used for injecting liquid into the bulb. The first one-way valve is fixedly connected to the flexible guide pipe in series, and the sleeve is connected with the piston rod in a sleeved mode. According to the device, the guide head is arranged, so that the uterus of a puerpera cannot be scratched when the device is used, and the problem that the uterus of the puerpera is stimulated due to scraping is solved.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

A wearable electronic system for the multi-modal monitoring and early detection of pre-eclampsia is disclosed. The system comprises a wristworn computing platform and a wirelessly coupled abdominal sensor unit. The wrist-worn device integrates a full-color touchscreen display (16); a rotary encoder (22) employing a Hall-effect sensor and a conductive crown surface (27) functioning as an ECG reference electrode; and a biometric sensor cluster comprising a four-photodiode optical array (17), a multi-wavelength LED array (21), a SioZ / ECG electrode assembly (19), and a skin-surface temperature sensor (18), all interfaced to a unified analog front-end (30). A central multi-core microcontroller unit (28), supported by high-bandwidth PSRAM (37) and NOR-Flash (29), orchestrates real-time signal processing for cuffless blood pressure estimation. A hardware security module (45) ensures hardware-rooted encryption of all maternal and fetal biometric data. The abdominal sensor utilizes a piezoelectric transducer and microphone to capture fetal heart rate and uterine contractions, enabling consolidated clinical-grade surveillance and automated risk classification for hypertensive disorders during pregnancy.